AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 201 filers reported holding AGIOS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.35 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $548,179 | -8.9% | 23,865 | +11.4% | 0.03% | -17.5% |
| Q4 2022 | $601,754 | -0.7% | 21,430 | +0.1% | 0.04% | 0.0% |
| Q3 2022 | $606,000 | +1.5% | 21,411 | -20.5% | 0.04% | +25.0% |
| Q2 2022 | $597,000 | -7.3% | 26,940 | +21.7% | 0.03% | -5.9% |
| Q1 2022 | $644,000 | +4.4% | 22,138 | +18.0% | 0.03% | -8.1% |
| Q4 2021 | $617,000 | -56.2% | 18,756 | -38.5% | 0.04% | -53.2% |
| Q3 2021 | $1,408,000 | +30.6% | 30,512 | +56.0% | 0.08% | +36.2% |
| Q2 2021 | $1,078,000 | +41.1% | 19,565 | +32.2% | 0.06% | +31.8% |
| Q1 2021 | $764,000 | +4.2% | 14,800 | -12.5% | 0.04% | -17.0% |
| Q4 2020 | $733,000 | -60.7% | 16,908 | -68.3% | 0.05% | -13.1% |
| Q3 2020 | $1,867,000 | +13.4% | 53,349 | +73.2% | 0.06% | +45.2% |
| Q2 2020 | $1,647,000 | +688.0% | 30,801 | +424.0% | 0.04% | +600.0% |
| Q1 2020 | $209,000 | -40.3% | 5,878 | -45.5% | 0.01% | +50.0% |
| Q3 2019 | $350,000 | – | 10,790 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |